Roxadustat effectiveness versus ESAs in peritoneal dialysis patients during the COVID-19 pandemic: A retrospective study
During the COVID-19 pandemic, both roxadustat and ESAs effectively improved renal anemia in PD patients, however, the roxadustat group experienced less additional costs for anemia correction and better medication compliance.
Authors
- Zhi Liu (ORCID: https://orcid.org/0000-0002-8695-9276)
- Kefan Zhou
- Xiaodan Wei
- Ruihua Huang (ORCID: https://orcid.org/0000-0002-8349-7803)
- Yanshan Tong
- Yasir Waheed (ORCID: https://orcid.org/0000-0002-5789-4215)
- Xinglei Zhou (ORCID: https://orcid.org/0000-0002-3734-7898)
- Jiaqi Zhao (ORCID: https://orcid.org/0000-0002-0601-3406)
- Fan Yang (ORCID: https://orcid.org/0009-0008-5468-4782)
- Lin Zhang (ORCID: https://orcid.org/0000-0003-2383-8431)
- Meng Chen (ORCID: https://orcid.org/0000-0002-7190-2162)
- Tianyu Li (ORCID: https://orcid.org/0000-0002-3719-1459)
- Kun Liu (ORCID: https://orcid.org/0000-0002-7276-7935)
- Shuang Li (ORCID: https://orcid.org/0000-0002-8188-7170)
- Jie Liu (ORCID: https://orcid.org/0000-0003-1398-5411)
- Xiaoyan Yu (ORCID: https://orcid.org/0000-0002-0748-3522)
- Chuankuo Tian
- Dong Sun
Institutions
- Xuzhou Medical College (CN)
- Beijing Aerospace General Hospital (CN)
- Kangda College of Nanjing Medical University
- Nanjing Medical University (CN)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-03-26
- DOI
- https://doi.org/10.1371/journal.pone.0320536
- Citations
- 1
- Primary Topic
- Erythropoietin and Anemia Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.77
Funders
- Xuzhou Science and Technology Program